Image courtesy CRT
CRT’s plans also to appoint commercial business managers to Cancer Research UK institutes in Cambridge, Manchester and Glasgow.
The expansion will meet growing demand to work on commercial proof of concept for projects initiated on the back of discoveries arising from basic research funded by Cancer Research UK and other partners throughout Europe and the US. Increasing the capacity will enable projects to be completed more quickly and consolidate CRT’s position in translational drug discovery.
Clive Stanway, Chief Scientific Officer, said the expansion will make CRT better equipped to meet the diverse demands of academic collaborators, and bridge the development gap to industry. “It will also create many new partnering opportunities, providing leading biotechnology and pharmaceutical companies with exciting and novel opportunities to supplement their pipelines.”
Keith Blundy, CEO of CRT, added, “Our plans will redefine traditional models of technology transfer.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
